Interactions between coagulation and complement - Their role in inflammation

Seminars in Immunopathology

Volumn 34, Issue 1, 2012, Pages 151-165

  Oikonomopoulou, Katerina ^a   Ricklin, Daniel ^a   Ward, Peter A ^b   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anaphylatoxin; Coagulation; Complement; Fibrinolysis; Inflammation; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT INHIBITOR; COMPSTATIN; DICOUMAROL; ECULIZUMAB; ENZYME PRECURSOR; HEPARIN; LIPOCORTIN 2; PEXELIZUMAB; PLASMIN; PROTEINASE; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; AUTACOID;

ADAPTIVE IMMUNITY; BLOOD CLOTTING DISORDER; COLITIS; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; ENTERITIS; ENZYME RELEASE; FIBRINOLYSIS; HEMOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; ISCHEMIA; ISCHEMIC HEART DISEASE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REPERFUSION INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SEPSIS; STREPTOCOCCUS INFECTION; STRUCTURE ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; ANIMAL; BLOOD; BLOOD CLOTTING; COMPLEMENT ACTIVATION; IMMUNOLOGY; METABOLISM;

ANIMALS; BLOOD COAGULATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; REPERFUSION INJURY; SEPSIS; THROMBOSIS;

EID: 84857532767     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-011-0280-x     Document Type: Review

References (173)

1. Reid KB, Porter RR (1981) The proteolytic activation systems of complement. Annu Rev Biochem 50:433-464
2. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785-797
3. Jackson CM, Nemerson Y (1980) Blood coagulation. Annu Rev Biochem 49:765-811
4. Adams RL, Bird RJ (2009) Review article: coagulation cascade and therapeutics update: relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anti-coagulants. Nephrology (Carlton) 14:462-470
5. Francis CW, Marder VJ (1987) Physiologic regulation and pathologic disorders of fibrinolysis. Hum Pathol 18:263-274 (Pubitemid 17051259)
6. Kane KK (1984) Fibrinolysis - a review. Ann Clin Lab Sci 14:443-449
7. Rawlings ND, Barrett AJ, Bateman A (2010) MEROPS: the peptidase database. Nucleic Acids Res 38:D227-D233
8. Rawlings ND (2010) Peptidase inhibitors in the MEROPS database. Biochimie 92:1463-1483
9. Barrett AJ, Rawlings ND, Woessner JF (2004) Handbook of proteolytic enzymes. Elsevier Academic Press, San Diego
10. Macfarlane RG (1948) Normal and abnormal blood coagulation: a review. J Clin Pathol 1:113-143
11. Lachmann P (2006) Complement before molecular biology. Mol Immunol 43:496-508
12. Hoffman R, Benz E Jr., Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (2005). Hematology: basic principles and practice. Elsevier Churchill Livingstone, Philadelphia
13. Walsh PN (2004) Platelet coagulation-protein interactions. Semin Thromb Hemost 30:461-471
14. Davie EW, Ratnoff OD (1964) Waterfall sequence for intrinsic blood clotting. Science 145:1310-1312
15. Hoffman M (2003) Remodeling the blood coagulation cascade. J Thromb Thrombolysis 16:17-20
16. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noel A (2003) Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 60:463-473 (Pubitemid 36459526)
17. Van de Werf FJ, Topol EJ, Sobel BE (2009) The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 7:14-20
18. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587
19. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1-43 (Pubitemid 40209385)
20. Riewald M, Ruf W (2003) Proteinase-activated receptor activation by coagulation proteinases. Drug Develop Res 59:400-407 (Pubitemid 37102191)
21. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264
22. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE (1999) Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 38:4572-4585
23. Laumonnier Y, Syrovets T, Burysek L, Simmet T (2006) Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes. Blood 107:3342-3349
24. Li Q, Laumonnier Y, Syrovets T, Simmet T (2007) Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 27:1383-1389 (Pubitemid 46809429)
25. Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6:132-142
26. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25:1265-1275 (Pubitemid 350089828)
27. Le FG, Kemper C (2009) Complement: coming full circle. Arch Immunol Ther Exp (Warsz) 57:393-407
28. Dunkelberger JR, Song WC (2010) Complement and its role in innate and adaptive immune responses. Cell Res 20:34-50
29. Markiewski MM, Lambris JD (2007) The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171:715-727 (Pubitemid 47440971)
30. Kemper C, Atkinson JP, Hourcade DE (2010) Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 28:131-155
31. Pangburn MK, Muller-Eberhard HJ (1986) The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 235:723-730 (Pubitemid 16071981)
32. Volanakis JE (1989) C3 convertases of complement. Molecular genetics, structure and function of the catalytic domains, C2 and B. Year Immunol 4:218-230
33. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J (2009) The role of the anaphylatoxins in health and disease. Mol Immunol 46:2753-2766
34. Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA, Cianflone K (2005) C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 280:23936-23944 (Pubitemid 40884882)
35. Ward PA (2009) Functions of C5a receptors. J Mol Med 87:375-378
36. Van Lith LH, Oosterom J, Van EA, Zaman GJ (2009) C5a-stimulated recruitment of beta-arrestin2 to the nonsignaling 7- transmembrane decoy receptor C5L2. J Biomol Screen 14:1067-1075
37. Bamberg CE, Mackay CR, Lee H, Zahra D, Jackson J, Lim YS, Whitfeld PL, Craig S, Corsini E, Lu B, Gerard C, Gerard NP (2010) The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 285:7633-7644
38. Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN (2009) The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol 46:1149-1162
39. Megyeri M, Mako V, Beinrohr L, Doleschall Z, Prohaszka Z, Cervenak L, Zavodszky P, Gal P (2009) Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J Immunol 183:3409-3416
40. Pham CT (2006) Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 6:541-550
41. Dulon S, Leduc D, Cottrell GS, D'Alayer J, Hansen KK, Bunnett NW, Hollenberg MD, Pidard D, Chignard M (2005) Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. Am J Respir Cell Mol Biol 32:411-419 (Pubitemid 40629326)
42. Schmidtchen A, Holst E, Tapper H, Bjorck L (2003) Elastase-producing Pseudomonas aeruginosa degrade plasma proteins and extracellular products of human skin and fibroblasts, and inhibit fibroblast growth. Microb Pathog 34:47-55 (Pubitemid 36287214)
43. Jagels MA, Travis J, Potempa J, Pike R, Hugli TE (1996) Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis. Infect Immun 64:1984-1991 (Pubitemid 26165656)
44. Wingrove JA, DiScipio RG, Chen Z, Potempa J, Travis J, Hugli TE (1992) Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem 267:18902-18907
45. Hajishengallis G, Lambris JD (2010) Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 31:154-163
46. Mollnes TE, Garred P, Bergseth G (1988) Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 73:484-488
47. Wiggins RC, Giclas PC, Henson PM (1981) Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 153:1391-1404 (Pubitemid 11067627)
48. DiScipio RG (1982) The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45:587-595
49. Hiemstra PS, Daha MR, Bouma BN (1985) Activation of factor B of the complement system by kallikrein and its light chain. Thromb Res 38:491-503 (Pubitemid 15041948)
50. Thoman ML, Meuth JL, Morgan EL, Weigle WO, Hugli TE (1984) C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. J Immunol 133:2629-2633 (Pubitemid 15204796)
51. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12:682-687 (Pubitemid 43865238)
52. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185:5628-5636
53. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V (2005) Platelet activation leads to activation and propagation of the complement system. J Exp Med 201:871-879 (Pubitemid 40524457)
54. Ghebrehiwet B, Silverberg M, Kaplan AP (1981) Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153:665-676 (Pubitemid 11155801)
55. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP (1983) Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71:1450-1456 (Pubitemid 13098935)
56. Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, Ekdahl KN (2010) Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One 5:e12889
57. Endo Y, Nakazawa N, Iwaki D, Takahashi M, Matsushita M, Fujita T (2009) Interactions of ficolin and mannose-binding lectin with fibrinogen/fibrin augment the lectin complement pathway. J Innate Immun 2:33-42
58. Krarup A, Wallis R, Presanis JS, Gal P, Sim RB (2007) Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2:e623
59. Gulla KC, Gupta K, Krarup A, Gal P, Schwaeble WJ, Sim RB, O'Connor CD, Hajela K (2010) Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 129:482-495
60. Platt JL, Dalmasso AP, Lindman BJ, Ihrcke NS, Bach FH (1991) The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur J Immunol 21:2887-2890
61. Marcum JA, Atha DH, Fritze LM, Nawroth P, Stern D, Rosenberg RD (1986) Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 261:7507-7517 (Pubitemid 17224759)
62. Zaferani A, Vives RR, van der PP, Hakvoort JJ, Navis GJ, van GH, Daha MR, Lortat-Jacob H, Seelen MA, van den BJ (2011) Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease. J Biol Chem 286:5359-5367
63. Polley MJ, Nachman R (1978) The human complement system in thrombin-mediated platelet function. J Exp Med 147:1713-1726 (Pubitemid 8372963)
64. Sims PJ, Wiedmer T (1991) The response of human platelets to activated components of the complement system. Immunol Today 12:338-342
65. Wiedmer T, Sims PJ (1985) Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J Biol Chem 260:8014-8019 (Pubitemid 15231447)
66. Ando B, Wiedmer T, Hamilton KK, Sims PJ (1988) Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J Biol Chem 263:11907-11914
67. Wiedmer T, Esmon CT, Sims PJ (1986) Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 68:875-880 (Pubitemid 17183846)
68. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ (1988) Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 263:18205-18212 (Pubitemid 19005097)
69. Hamilton KK, Hattori R, Esmon CT, Sims PJ (1990) Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 265:3809-3814
70. Peerschke EI, Reid KB, Ghebrehiwet B (1993) Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 178:579-587 (Pubitemid 23218206)
71. Skoglund C, Wettero J, Tengvall P, Bengtsson T (2010) C1q induces a rapid up-regulation of P-selectin and modulates collagen-and collagen-related peptide-triggered activation in human platelets. Immunobiology 215:987-995
72. Polley MJ, Nachman RL (1983) Human platelet activation by C3a and C3a des-arg. J Exp Med 158:603-615 (Pubitemid 13049411)
73. Gushiken FC, Han H, Li J, Rumbaut RE, fshar-Kharghan V (2009) Abnormal platelet function in C3-deficient mice. J Thromb Haemost 7:865-870
74. Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, Halperin JA (2003) Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 18:217-227 (Pubitemid 36262997)
75. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B (2010) Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 184:2686-2692
76. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y (1997) C5a induces tissue factor activity on endothelial cells. Thromb Haemost 77:394-398 (Pubitemid 27084936)
77. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD (2006) A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 177:4794-4802 (Pubitemid 44469814)
78. Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, DeAngelis RA, Lambris JD, Ritis KD (2008) C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 180:7368-7375
79. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A (1997) The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 185:1619-1627 (Pubitemid 27203258)
80. Sillaber C, Baghestanian M, Bevec D, Willheim M, Agis H, Kapiotis S, Fureder W, Bankl HC, Kiener HP, Speiser W, Binder BR, Lechner K, Valent P (1999) The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 162:1032-1041 (Pubitemid 29035431)
81. Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, Fritsch G, Printz D, Binder BR, Schatzl G, Zwirner J, Maurer G, Huber K, Valent P (2002) C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 100:517-523 (Pubitemid 34761114)
82. Wojta J, Huber K, Valent P (2003) New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. Pathophysiol Haemost Thromb 33:438-441 (Pubitemid 40278721)
83. Levi M, van der Tom P (2010) Inflammation and coagulation. Crit Care Med 38:S26-S34
84. Levi M, van der Tom P (2005) Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 15:254-259 (Pubitemid 41437908)
85. Markiewski MM, DeAngelis RA, Lambris JD (2006) Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol Immunol 43:45-56 (Pubitemid 41021521)
86. Markiewski MM, DeAngelis RA, Strey CW, Foukas PG, Gerard C, Gerard N, Wetsel RA, Lambris JD (2009) The regulation of liver cell survival by complement. J Immunol 182:5412-5418
87. Shebuski RJ, Kilgore KS (2002) Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 300:729-735 (Pubitemid 34164973)
88. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U (2005) Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 96:1233-1239 (Pubitemid 40962100)
89. Burstein SA, Peng J, Friese P, Wolf RF, Harrison P, Downs T, Hamilton K, Comp P, Dale GL (1996) Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 14 (Suppl 1):154-162 (Pubitemid 126687204)
90. Verardi S, Page RC, Ammons WF, Bordin S (2007) Differential chemokine response of fibroblast subtypes to complement C1q. J Periodontal Res 42:62-68
91. Lidington EA, Haskard DO, Mason JC (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 96:2784-2792
92. Campbell W, Okada N, Okada H (2001) Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 180:162-167 (Pubitemid 32472860)
93. Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271:16603-16608 (Pubitemid 26239017)
94. Levi M, Opal SM (2006) Coagulation abnormalities in critically ill patients. Crit Care 10:222
95. Degen JL, Bugge TH, Goguen JD (2007) Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 5(Suppl 1):24-31 (Pubitemid 46958813)
96. Hecke F, Schmidt U, Kola A, Bautsch W, Klos A, Kohl J (1997) Circulating complement proteins in multiple trauma patients - correlation with injury severity, development of sepsis, and outcome. Crit Care Med 25:2015-2024 (Pubitemid 28007240)
97. Markiewski MM, DeAngelis RA, Lambris JD (2008) Complexity of complement activation in sepsis. J Cell Mol Med 12:2245-2254
98. Ward PA, Gao H (2009) Sepsis, complement and the dysregulated inflammatory response. J Cell Mol Med 13:4154-4160
99. Castellheim A, Brekke OL, Espevik T, Harboe M, Mollnes TE (2009) Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 69:479-491
100. Daniels R, Nutbeam T (2010) ABC of Sepsis. Blackwell Publishing Ltd, Chichester
101. Rittirsch D, Flierl MA, Ward PA (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8:776-787
102. Ward PA (2004) The dark side of C5a in sepsis. Nat Rev Immunol 4:133-142
103. Laudes IJ, Chu JC, Sikranth S, Huber-Lang M, Guo RF, Riedemann N, Sarma JV, Schmaier AH, Ward PA (2002) Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 160:1867-1875 (Pubitemid 34525666)
104. Knoebl P (2010) Blood coagulation disorders in septic patients. Wien Med Wochenschr 160:129-138
105. Gando S (2010) Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 38:S35-S42
106. Deitch EA (1992) Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 216:117-134
107. Barie PS, Hydo LJ, Pieracci FM, Shou J, Eachempati SR (2009) Multiple organ dysfunction syndrome in critical surgical illness. Surg Infect (Larchmt) 10:369-377
108. Ten Cate H, Schoenmakers SH, Franco R, Timmerman JJ, Groot AP, Spek CA, Reitsma PH (2001) Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med 29:S95-S97
109. Younger JG, Bracho DO, Chung-Esaki HM, Lee M, Rana GK, Sen A, Jones AE (2010) Complement activation in emergency department patients with severe sepsis. Acad Emerg Med 17:353-359
110. Semple JW, Freedman J (2010) Platelets and innate immunity. Cell Mol Life Sci 67:499-511
111. Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neumann FJ (1997) Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 23:379-385 (Pubitemid 27196965)
112. Ekdahl KN, Nilsson B (1995) Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b. J Immunol 154:6502-6510
113. Nilsson-Ekdahl K, Nilsson B (2001) Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1. Eur J Immunol 31:1047-1054
114. Hack CE, Nuijens JH, Felt-Bersma RJ, Schreuder WO, Eerenberg- Belmer AJ, Paardekooper J, Bronsveld W, Thijs LG (1989) Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 86:20-26 (Pubitemid 19039532)
115. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, Zetoune FS, Gerard NP, Cianflone K, Kohl J, Gerard C, Sarma JV, Ward PA (2008) Functional roles for C5a receptors in sepsis. Nat Med 14:551-557 (Pubitemid 351655216)
116. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J (2005) C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22:415-426 (Pubitemid 40545108)
117. Riedemann NC, Guo RF, Gao H, Sun L, Hoesel M, Hollmann TJ, Wetsel RA, Zetoune FS, Ward PA (2004) Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. J Immunol 173:1355-1359 (Pubitemid 38924315)
118. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD (2007) Complement and coagulation: strangers or partners in crime? Trends Immunol 28:184-192 (Pubitemid 46476881)
119. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ (1993) Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 82:1192-1196 (Pubitemid 23253993)
120. Karpman D, Manea M, Vaziri-Sani F, Stahl AL, Kristoffersson AC (2006) Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 32:128-145
121. Coppola L, Guastafierro S, Verrazzo G, Coppola A, De LD, Tirelli A (2002) C1 inhibitor infusion modifies platelet activity in hereditary angioedema patients. Arch Pathol Lab Med 126:842-845 (Pubitemid 34761643)
122. Nangaku M, Couser WG (2005) Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 9:183-191 (Pubitemid 41414116)
123. Shushakova N, Tkachuk N, Dangers M, Tkachuk S, Park JK, Hashimoto K, Haller H, Dumler I (2005) Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci 118:2743-2753 (Pubitemid 40932898)
124. Mocco J, Wilson DA, Komotar RJ, Sughrue ME, Coates K, Sacco RL, Elkind MS, Connolly ES Jr (2006) Alterations in plasma complement levels after human ischemic stroke. Neuro-surgery 59:28-33
125. Banz Y, Rieben R (2011) Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med doi:10.3109/07853890.2010. 535556
126. Cervera A, Planas AM, Justicia C, Urra X, Jensenius JC, Torres F, Lozano F, Chamorro A (2010) Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One 5:e8433
127. Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Ronnblom L, Sturfelt G, Eloranta ML, Bengtsson AA (2009) C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 60:3081-3090
128. Robson MG, Walport MJ (2001) Pathogenesis of systemic lupus erythematosus (SLE). Clin Exp Allergy 31:678-685 (Pubitemid 32823811)
129. Palatinus A, Adams M (2009) Thrombosis in systemic lupus erythematosus. Semin Thromb Hemost 35:621-629
130. Nilsson B, Korsgren O, Lambris JD, Ekdahl KN (2010) Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol 31:32-38
131. Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I, Panagoutsos S, Passadakis P, Vargemezis V, Magotti P, Qu H, Mollnes TE, Ritis K, Lambris JD (2010) Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116:631-639
132. Brenner P, Keller M, Beiras-Fernandez A, Uchita S, Kur F, Thein E, Wimmer C, Hammer C, Schmoeckel M, Reichart B (2010) Prevention of hyperacute xenograft rejection through direct thrombin inhibition with hirudin. Annals of Transplantation: quarterly of the Polish Transplantation Society 15:30-37
133. Freue GV, Sasaki M, Meredith A, Gunther OP, Bergman A, Takhar M, Mui A, Balshaw RF, Ng RT, Opushneva N, Hollander Z, Li G, Borchers CH, Wilson-McManus J, McManus BM, Keown PA, McMaster WR (2010) Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics 9:1954-1967
134. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M (2010) Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 28:254-257
135. Lu F, Fernandes SM, Davis AE III (2010) The role of the complement and contact systems in the dextran sulfate sodium - induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 298:G878-G883
136. Cugno M, Tedeschi A, Crosti C, Marzano AV (2009) Activation of blood coagulation in autoimmune skin disorders. Expert Rev Clin Immunol 5:605-613
137. Wagner E, Frank MM (2010) Therapeutic potential of complement modulation. Nat Rev Drug Discov 9:43-56
138. Qu H, Ricklin D, Lambris JD (2009) Recent developments in low molecular weight complement inhibitors. Mol Immunol 47:185-195
139. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110:4123-4128 (Pubitemid 350248472)
140. Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, Porto I, Andreotti F, Crea F, Banning AP (2008) Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 136:884-893
141. Flierl MA, Rittirsch D, Nadeau BA, Day DE, Zetoune FS, Sarma JV, Huber-Lang MS, Ward PA (2008) Functions of the complement components C3 and C5 during sepsis. FASEB J 22:3483-3490
142. Ricklin D, Lambris JD (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 632:273-292
143. Chi ZL, Yoshida T, Lambris JD, Iwata T (2010) Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol 703:127-135
144. Potentia (2007) Potentia Pharmaceuticals announces initiation of Phase I clinical trials to evaluate its lead compound for age-related macular degeneration. Potentia Press Release, April 5, 2007
145. Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P, Ivanciu L, Lupu C, Mollnes TE, Taylor FB, Kinasewitz G, Lambris JD, Lupu F (2010) Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116:1002-1010
146. Thuerer GR, Angevine DM (1949) Influence of dicumarol on streptococcic infection in rabbits. Arch Pathol (Chic) 48:274-277
147. Weiler JM, Linhardt RJ (1991) Antithrombin III regulates complement activity in vitro. J Immunol 146:3889-3894
148. Ranjbaran H, Wang Y, Manes TD, Yakimov AO, Akhtar S, Kluger MS, Pober JS, Tellides G (2006) Heparin displaces interferon-gamma- inducible chemokines (IP-10, I-TAC, andMig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation 114:1293-1300 (Pubitemid 44402055)
149. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, Sydow K, Lau D, Szocs K, Klinke A, Kubala L, Berglund L, Schrepfer S, Deuse T, Haddad M, Risius T, Klemm H, Reichenspurner HC, Meinertz T, Heitzer T (2006) Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 113:1871-1878 (Pubitemid 43739399)
150. Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, Prestwich GD, MacArthur RB, Walters BB, Hoidal JR, Kennedy TP (2010) Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin - induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 299:C97-C110
151. Davis AE III (2005) The pathophysiology of hereditary angioedema. Clin Immunol 114:3-9
152. Kaplan AP (2010) Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 126:918-925
153. Antoniu SA (2011) Therapeutic approaches in hereditary angioedema. Clin Rev Allergy Immunol doi:10.1007/s12016-011-8254-2
154. Petersen SV, Thiel S, Jensen L, Vorup-Jensen T, Koch C, Jensenius JC (2000) Control of the classical and the MBL pathway of complement activation. Mol Immunol 37:803-811
155. Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T (2000) Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 165:2637-2642 (Pubitemid 30660711)
156. Jiang H, Wagner E, Zhang H, Frank MM (2001) Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 194:1609-1616 (Pubitemid 33126811)
157. Jansen PM, Eisele B, de Jang I, Chang A, Delvos U, Taylor FB Jr, Hack CE (1998) Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 160:475-484 (Pubitemid 28116764)
158. Levi M, Lowenberg E, Meijers JC (2010) Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost 36:550-557
159. Levi M, van der Tom P (2008) The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 34:459-468
160. Crowther MA, Marshall JC (2001) Continuing challenges of sepsis research. JAMA 286:1894-1896 (Pubitemid 33010244)
161. Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T (2010) In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 33:282-288
162. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:31-41 (Pubitemid 44921064)
163. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878
164. Levi M, Schouten M, van der Tom P (2008) Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 34:742-746
165. Opal SM (2000) Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 28:S34-S37
166. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4:90-97
167. Sarangi PP, Lee HW, Kim M (2010) Activated protein C action in inflammation. Br J Haematol 148:817-833
168. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709 (Pubitemid 32204987)
169. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL (2007) Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 176:483-490 (Pubitemid 47358102)
170. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT (2009) Extracellular histones are major mediators of death in sepsis. Nat Med 15:1318-1321
171. Goring K, Huang Y, Mowat C, Leger C, Lim TH, Zaheer R, Mok D, Tibbles LA, Zygun D, Winston BW (2009) Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C. Am J Physiol Cell Physiol 296:C1140-C1150
172. Mosnier LO, Yang XV, Griffin JH (2007) Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 282:33022-33033 (Pubitemid 350159287)
173. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH (2004) Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104:1740-1744 (Pubitemid 39202282)